Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Analytik Jena Subsidiary Obtained Approval for Two New Assays

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
ELISA-based tests for detection of PRRSV.

AJ Roboscreen, an Analytik Jena company, recently obtained the approval for two new assays for screening of swine sera for PRRSV (porcine reproductive and respiratory syndrome virus) antibodies and for evaluation.

The new ELISA-based tests differentiate into PRRSV Type I (Europe-Type) and Type II (North America-Type).

The ELISA (Enzyme Linked Immunosorbent Assay) is an immunoassay to detect proteins in liquid samples.

"At present PRRSV causes the most important economical loss in pig industry. According to estimates, 70-80 % of all enterprises in Germany are affected by PRRSV. At least 30,000 to 35,000 tests are used for sow and piglet enterprises in Saxony per year; this corresponds to 40 % of all sows in this federal state in Germany. Resulting reproductive problems and pneumonia lead to reduced growth and vulnerability for secondary infection", said Alexander Berka, Manager of the Life Science business unit at Analytik Jena AG.

Infected animals quickly spread PRRSV within a flock via contaminated body fluids.

Losses of 25 € to 250 € per breeding sow and year are estimated. For this reason several vaccination programs are trying to raise immunity of the flocks.

"Effective containment substantially depends on early identification and quick isolation or removal of infected animals", continued Alexander Berka.

Based on a licensing agreement with the Fraunhofer Institute for Cell Therapy and Immunology, Analytik Jena developed the two new assays PRRSV DETECT-ELISA and PRRSV NA/EU TYP-ELISA.

The new ELISAs currently are a unique solution on the market for PRRSV antibody detection and differentiation for effective control and containment of this infectious and economically devastating disease.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Analytik Jena AG Supports Bone Marrow Donation Organization
Company to support DKMS in the fight against blood cancer.
Saturday, June 20, 2015
Analytik Jena AG Receives Major Order from China
Delivery of EUR 2.5 m in instruments from both core business units of Analytical Instrumentation and Life Science.
Friday, May 08, 2015
Analytik Jena to Acquire Bruker’s ICP-MS Business
Analytik Jena AG has signed a binding agreement to acquire the ICP-MS business of Bruker, the transaction is expected to close in September 2014.
Monday, August 18, 2014
Analytik Jena AG Completes Merger of CyBio AG
Merger became effective upon entry into the commercial register of Analytik Jena AG.
Thursday, July 10, 2014
Analytik Jena CEO Klaus Berka Becomes an Advisor of the Fraunhofer IZI
Klaus Berka to advise the institute's management and the Executive Board of the Fraunhofer Gesellschaft.
Saturday, May 17, 2014
CyBio to be Merged into Analytik Jena
Analytik Jena AG is planning to merge the business of its subsidiary CyBio AG with its core business in the Life Science business unit.
Friday, April 11, 2014
Analytik Jena Appoints New MD at Japanese Subsidiary
Dr. Marco Tilgner has been appointed new managing director of the Japanese subsidiary AJ Japan as of January 1, 2014.
Monday, December 09, 2013
Analytik Jena Establishes Subsidiary in Thailand
New company to bolster Analytik Jena’s activities in the Southeast Asian market.
Tuesday, May 07, 2013
Analytik Jena to Develop Products for Sepsis Diagnostics
Cooperation to continue with the scientific centers for sepsis research in Jena.
Tuesday, May 07, 2013
Analytik Jena to Develop Products for Sepsis Diagnostics
Integration of a core team of former employees in the Life Science business unit. Cooperation to continue with the scientific centers for sepsis research in Jena.
Tuesday, May 07, 2013
Analytik Jena Increases Stake in Ilmenau-Based ETG to 80.0%
ETG already generates approximately 85.0% of its sales with Analytik Jena.
Friday, April 12, 2013
Analytik Jena AG Acquires UVP, LLC
UVP is a globally-operating provider of predominantly digital imaging systems for applications in proteomics, genomics and plant and animal sciences.
Tuesday, April 02, 2013
Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%
The Jena-based manufacturer of analytical instrumentation technology, life science instruments and optoelectronics has thus integrated another subsidiary further into the Group.
Monday, April 23, 2012
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos